Therese M L Andersson
Overview
Explore the profile of Therese M L Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abalo K, Ekberg S, Andersson T, Pahnke S, Albertsson-Lindblad A, Smedby K, et al.
Hemasphere
. 2024 Jul;
8(7):e121.
PMID: 38978637
Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the...
2.
Myklebust T, Aagnes B, Nilssen Y, Rutherford M, Lambert P, Andersson T, et al.
Br J Cancer
. 2023 Jul;
129(5):819-828.
PMID: 37433898
Background: Routine reporting of cancer patient survival is important, both to monitor the effectiveness of health care and to inform about prognosis following a cancer diagnosis. A range of different...
3.
Krakowski I, Habel H, Nielsen K, Ingvar C, Andersson T, Girnita A, et al.
Br J Dermatol
. 2023 Jan;
188(1):32-40.
PMID: 36689497
Background: Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse...
4.
Vigneswaran H, Warnqvist A, Andersson T, Leval A, Eklund M, Nordstrom T, et al.
Scand J Urol
. 2021 Jun;
55(4):299-306.
PMID: 34096469
Background: Studies describing treatment utilization for castration-resistant prostate cancer (CRPC) are limited. We aimed to describe the treatment utilization of a contemporary population-based CRPC cohort between 2006 and 2016. Methods:...
5.
Qaderi S, Andersson T, Dickman P, de Wilt J, Verhoeven R
J Clin Epidemiol
. 2021 Apr;
137:92-103.
PMID: 33836257
Objective: Specific survival estimates are needed for the increasing number of colorectal cancer (CRC) survivors. The aim of this population-based study was to determine conditional loss in expectation of life...
6.
Weibull C, Lambert P, Eloranta S, Andersson T, Dickman P, Crowther M
Stat Med
. 2021 Feb;
40(9):2139-2154.
PMID: 33556998
As cancer patient survival improves, late effects from treatment are becoming the next clinical challenge. Chemotherapy and radiotherapy, for example, potentially increase the risk of both morbidity and mortality from...
7.
Biccler J, Glimelius I, Eloranta S, Smeland K, de Nully Brown P, Jakobsen L, et al.
J Clin Oncol
. 2019 Feb;
37(9):703-713.
PMID: 30726176
Purpose: Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at...
8.
Weibull C, Bjorkholm M, Glimelius I, Lambert P, Andersson T, Smedby K, et al.
Int J Cancer
. 2019 Jan;
145(5):1200-1208.
PMID: 30666628
While Hodgkin lymphoma (HL) survival has improved, treatment-related complications remain a concern. As a measure of treatment-related diseases of the circulatory system (DCS) we report excess incidence of DCS and...
9.
Hultcrantz M, Bjorkholm M, Landgren O, Kristinsson S, Andersson T
Ann Intern Med
. 2018 Aug;
169(4):268.
PMID: 30128518
No abstract available.
10.
Hultcrantz M, Bjorkholm M, Dickman P, Landgren O, Derolf A, Kristinsson S, et al.
Ann Intern Med
. 2018 Jan;
168(5):317-325.
PMID: 29335713
Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at increased risk for thrombotic events. However, no population-based study has estimated this excess risk compared with matched control participants....